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1  |  INTRODUC TION
Obesity is worldwide one of the most important causes of prevent-
able deaths and is affecting a large part of patients with end-stage 
renal disease (ESRD).1–4 The relative risk of developing ESRD rises 
with an increasing body mass index (BMI).3,5 Ejerblad et al found 
that	obesity	class	I	(BMI	≥	30	kg/m2) among men and obesity class 
II	(BMI	≥	35)	among	women	anytime	during	their	lifetime	was	asso-
ciated with a 3- to 4-time increased risk of chronic kidney disease 
(CKD).6 Kidney transplant candidates and recipients are increasingly 
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Abstract
Patients with class II and III obesity and end-stage renal disease are often ineligi-
ble for kidney transplantation (KTx) due to increased postoperative complications 
and technically challenging surgery. Bariatric surgery (BS) can be an effective solu-
tion for KTx candidates who are considered inoperable. The aim of this study is to 
evaluate outcomes of KTx after BS and to compare the outcomes to obese recipi-
ents	 (BMI	≥	35	kg/m2) without BS. This retrospective, single-center study included 
patients who received KTx after BS between January 1994 and December 2018. 
The primary outcome was postoperative complications. The secondary outcomes 
were graft and patient survival. In total, 156 patients were included, of whom 23 
underwent BS prior to KTx. There were no significant differences in postoperative 
complications.	After	a	median	follow-up	of	5.1	years,	death-censored	graft	survival,	
uncensored graft survival, and patient survival were similar to controls (log rank test 
p	=	.845,	.659,	and	.704,	respectively).	Dialysis	pre-transplantation	(Hazard	Ratio	(HR)	
2.55; 95%CI 1.03–6.34, p = .043) and diabetes (HR 2.41; 95%CI 1.11–5.22, p	=	.027)	
were	independent	risk	factors	for	all-cause	mortality.	A	kidney	from	a	deceased	donor	
was an independent risk factor for death-censored graft loss (HR 1.98; 95%CI 1.04–
3.79,	p = .038). Patients who received a KTx after BS have similar outcomes as obese 
transplant recipients.
K E Y W O R D S
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becoming obese.7,8 Due to the shortage of transplant organs, ESRD 
patients wait on dialysis, during which they risk gaining even more 
weight.9 Paradoxically, patients with obesity are reported to have 
a longer survival on dialysis compared with lean patients,9 possibly 
resulting in an increase in obese transplant candidates. Survival after 
transplantation, however, is worse in the population with obesity 
compared with normal weight recipients.10 In several centers in the 
Netherlands,	a	BMI	≥	35	kg/m2 was considered an absolute contra-
indication for transplantation. However, guidelines are becoming 
less strict and there is no consensus on whether or not a patient is 
ineligible for transplantation based on their weight or BMI.11 Even 
with less strict guidelines, patients are more often found ineligible 
for transplantation based on their BMI.12 In a multivariate analysis, 
Lassalle	et	al	found	that	patients	with	a	BMI	>	31	kg/m2 at the start 
of dialysis were less likely to receive a kidney transplant.13 Kidney 
transplantation in the obese patient is often technically more chal-
lenging due to the excess abdominal fat and obesity is associated 
with more postoperative complications as wound infection, delayed 
graft function and acute, and chronic rejection.14–17 In order to re-
duce these complications after KTx, weight loss resulting in a BMI 
less than 30 kg/m2 is recommended.14 Bariatric surgery (BS) has 
been proven to be the most effective treatment to achieve long-
term	weight	loss.	BS	is	indicated	in	patients	with	a	BMI	≥	35	kg/m2 
and at least one obesity-related comorbidity or in patients with a 
BMI	≥	40	kg/m2.18,19	Andalib	et	al	analyzed	234	patients	on	dialysis	
who had underwent primary BS and concluded that the morbidity 
and mortality is acceptable compared with patients who were not 
depending on dialysis. Recent studies show that excess weight loss 
(EWL)	in	kidney	transplant	candidates	or	recipients	after	BS	is	com-
parable to the non-renal disease population.20,21	A	few	case	studies	
report the use of BS to improve eligibility for transplantation after 
initial rejection based on BMI.22–24
In a more recent study, 42 patients underwent KTx after laparo-
scopic sleeve gastrectomy with a decrease of patients with diabetes, 
hypertension, and number of antihypertensive medications used.25 
Post-transplantation outcome among these patients were compa-
rable to non-obese patients. This is remarkable considering these 
patient would have otherwise been ineligible for KTx.
The aim of this study is to compare complications, mortality, 
graft, and patient survival after kidney transplantation in patients 
who had BS prior to transplantation with kidney transplant recipi-
ents	with	obesity	class	II	and	III	(BMI	≥	35)	without	BS.
2  |  MATERIAL S AND METHODS
2.1  |  Study population
This retrospective, single-center cohort study was conducted at the 
Erasmus	Medical	Center	in	Rotterdam,	The	Netherlands.	The	selec-
tion process is illustrated in Figure 1. Between January 1994 and 
December 2018, 2598 adult patients received a kidney transplant. 
The records of all kidney transplant recipients were screened on a 
medical history of bariatric surgery. Types of BS that were included 
were gastric banding (GB), sleeve gastrectomy (SG), Roux-en-Y gas-
tric bypass (RYGB). The WHO classification of weight was used to 
determine severity of obesity and to established inclusion criteria. 
Bariatric surgery is indicated in patients with obesity class II (BMI 
35.0–39.9)	and	class	III	(BMI	≥	40)	and	are	therefore	included	in	the	
control group, the transplant only (TO). Patients who underwent BS 
F I G U R E  1 Flowchart	of	inclusion	process.	BMI,	Body	mass	index
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after KTx were included in the control group and censored from the 
date	they	underwent	BS.	All	data	were	obtained	from	the	Electronic	
Patient Dossier of Erasmus Medical Center until January 1, 2020.
In this center, patients were mainly deemed unsuitable for trans-
plantation based on distribution of the abdominal fat and technical 
impossibility of performing the implantation in the iliac fossa. From a 
surgical point of view, subcutaneous abdominal fat is preferred over 
visceral fat because it can easier—and therefore safer—be manipulated 
to facilitate kidney transplantation. The immobile visceral fat impairs 
the view of the surgical field which hinders the implantation of the kid-
ney. Patient eligibility for kidney transplantation was determined by a 
group of highly experienced surgeons who each performed over 200 
kidney transplantations. They based their opinion on whether or not 
implantation of the transplant is technically possible. The mobility of 
the abdomen is assessed to determine the accessibility to the iliac ar-
tery	and	vein.	The	abdomen	is	mobilized	with	the	hands	of	the	surgeon	
during physical examination at the outpatient clinic and this simulation 




imaging was not used to determine eligibility for KTx.
2.2  |  Outcomes
The primary outcome measure of this study was postoperative compli-
cations within 3 months after transplantation in patients who under-
went BS prior to transplantation (BSG) compared with patients with 
obesity class II and III at time of transplantation (TO). Postoperative 
complications were registered up to 3 months after transplantation. 
Post-transplant diabetes mellitus (PTDM) was defined as the initiation 
of any antidiabetic medication after transplantation. Incisional hernia 
of the Gibson incision after kidney transplantation was recorded up to 
one	year	after	transplantation.	All	postoperative	complications	were	
recorded, and severity was scored according to the Clavien-Dindo 
classification. Severe complications were defined as complications 
with Clavien-Dindo grade IIIa or higher.
For secondary outcomes, graft and patient survival, mortality 
and	early	graft	loss	(EGL)	were	investigated.	Postoperative	mortal-
ity was defined as mortality during hospital stay or within 90 days 
after transplantation. Patient survival was calculated from the date 
of transplantation to the date of an event or the last moment of fol-
low-up.	Graft	failure	was	defined	as	primary	non-function	(PNF)	of	
the graft, the initiation of renal replacement therapy/dialysis, trans-
plant nephrectomy or re-transplantation. Delayed Graft Function 
(DGF) was defined as the need of resuming dialysis within 1 week 
after	transplantation.	PNF	was	defined	as	the	failure	of	a	graft	with-
out detectable technical or immunological problems within 3 months 
after	transplantation.	EGL	was	defined	as	the	loss	of	a	graft	within	
30 days of transplantation or primary non-function. Death-censored 
graft survival was calculated from the date of transplantation to the 
date of graft loss. Patients who died with a functioning graft and 
patients that were lost to follow-up were censored. Uncensored 
graft survival was calculated from the time of transplantation to the 
date of graft loss or patient death. Patients who were lost to follow 
up were censored from the last moment of follow-up.
2.3  |  Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics 24. 
Baseline characteristics and outcomes were described as counts 
and percentages for categorical variables. For continuous variables, 
means and standard deviations (SD) were given for normally dis-
tributed variables and medians and interquartile ranges (IQR) for 
skewed continuous variables. Differences in postoperative compli-
cations between groups were compared using the chi-square test 
or Fisher's exact tests when the expected count was lower than 5. 
For continuous variables, the Mann-Whitney U test was used. Odds 
ratios and 95% CI were calculated using univariate logistical regres-
sion. Propensity scored matching was done to match the two groups 
to correct for difference in baseline characteristics in a 1:1 ratio. 
Patients were matched based on time of dialysis treatment, diabetic 
status, and smoking status. Graft survival and patient survival were 
estimated with the Kaplan-Meier method, and curves were com-
pared using the log rank test. Multivariable Cox regression analyses 
were used to identify risk factors for death-censored graft loss and 
patient death using preselected variables. The enter method was 




medication consisting of tacrolimus, mycophenolate mofetil (MMF), 
and	prednisone.	Normally,	prednisone	is	gradually	tapered	over	the	
first 3 months followed by complete withdrawal. Blood levels are 
regularly	checked,	and	dosages	are	adjusted	to	optimize	blood	levels.
2.5  |  Ethical approval
This study was approved by the Ethics Committee of the Erasmus 
Medical Center Rotterdam and was conducted in accordance with 
the provisions of the declaration of Helsinki.
3  |  RESULTS
3.1  |  Study population
Of 156 included patients, 23 patients were included in the BSG and 
133 patients received a kidney transplant with obesity class II and 
III (TO). In the group that received a kidney transplant after bariatric 
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TA B L E  1 Baseline	characteristics	of	kidney	transplant	recipients	with	obesity	class	II	and	III	compared	with	patients	who	underwent	BS	
prior to transplantation: overall and propensity score-matched cohort
Before PSM (n = 156) After PSM (n = 46)
TO (n = 133) BSG (n = 23) p-value TO (n = 23) BSG (n = 23) p-value
Age,	median	(IQR) 53.1 (40.9–63.3) 55.5 (40.4–61.5) .249 51.4 (38.9–63.5) 55.5 (40.4–61.5) .974
Male, n (%) 64 (48.1) 7	(30.4) .088 13 (56.5) 8	(34.7) .139
BMI (kg/m2) at KTx, 
median (IQR)
36.7	(35.5–38.8) 33.8 (31.6–34.1) <.001a  36.8 (36.0–39.3) 33.8 (31.6–34.1) <.001a 
Smokers, n (%) 69 (51.9) 5	(21.7) <.001a  8 (34.8) 5	(21.7) .326
Medical history, n (%)
Diabetes mellitus 52 (39.1) 14 (60.9) .043a  12	(47.8) 14 (60.9) .369
Cardiac disease 54 (44.6) 12	(47.8) .300 10 (43.5) 12	(47.8) .904
CVA/TIA 8 (6.0) 0 (0.0) .227 1 (4.3) 0 (0.0) .500
COPD 8 (6.0) 4	(17.4) .079 4	(17.4) 4	(17.4) .000
Thromboembolic 
events
17	(12.8) 2	(8.7) .443 6 (26.1) 2	(8.7) .121
Peripheral arterial 
disease
11 (8.3) 1 (4.3) .445 3 (13.0) 1 (4.3) .304
Dialysis treatment, n (%) 98	(73.7) 17	(73.9) .603 20	(87.0) 17	(73.9) .265
Time of dialysis in 
months, median 
(IQR)
24 (15–38) 30 (21–61) .026a  31 (21–50) 30 (21–61) .806
Type of donor, n (%)
Living 90	(67.7) 13 (56.5) .209 11	(47.8) 13 (56.5) .555
DBD 15 (11.3) 6 (26.0) 5	(21.7) 6 (18.2)
DCD 27	20.3) 5	(21.7) 7	(30.1) 5 (15.2)
Donor age, median (IQR) 52 (40–62) 55 (46–61) .779 48 (38–59) 55 (46–61) .442
ECD, n (%) 48 (36.1) 10 (30.3) .498 4	(17.4) 10 (30.3) .054
First transplant, n (%) 109 (82.0) 21 (91.3) .215 16	(70.0) 21 (91.3) .067
HLA	mismatch,	n
0 7 0 3 0
1–2 28 5 6 5
3–4 57 12 5 12
5–6 43 6 8 6
ABO	compatible,	n (%) 129	(97.0) 22	(95.7) .555 21 (91.3) 22	(95.7) .500
Cause of ESRD, n (%)
Diabetes mellitus 37	(27.8) 9 (39.1) 9 (39.1) 9 (39.1)
Hypertension 22 (16.5) 3 (13.0) 3 (130) 3 (13.0)
FSGS 18 (13.5) 5	(21.7) 2	(8.7) 5	(21.7)
Nephritic	syndrome 22 (16.5) 1 (4.3) 1 (4.3) 1 (4.3)
Polycystic kidney 
disease
12 (6.0) 2	(8.7) 5	(21.7) 2	(8.7)
Congenital kidney 
disease
8 (6.0) 0 (0) 0 (0) 0 (0)
Other 14 (10.5) 3 (13.0) 3 (13.0) 3 (13.0)
Abbreviations:	BMI,	Body	mass	index;	BSG,	Bariatric	surgery	group;	COPD,	Chronic	Obstructive	Pulmonary	Disease;	CVA,	Cerebrovascular	Accident;	
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surgery, 13% of patients had a BMI between 25 and 29.9 (n = 3), 65% 
of patients had a BMI between 30 and 34.9 (n = 15), 22% had a BMI 
between 35 and 39.9 (n = 5) and no one had a BMI above 40. In the 
transplant only group, 89% had a BMI between 35 and 39.9 (n = 118) 
and 11% had a BMI above 40 (n = 15). Of the transplant only patients, 
15 patients underwent BS after KTx and were censored graft and pa-
tient survival from the moment they underwent BS. Table 1 shows 
baseline characteristics of all patients included. BMI at transplanta-
tion was 33.6 kg/m2	(31.4–34.7)	in	the	BSG	compared	with	36.7	kg/
m2 (35.5–38.8) in TO. The BSG received a significantly longer period 
of dialysis treatment compared with the TO, 40 months (22–83) ver-
sus 24 months (15–38, p = .026). The prevalence of diabetes mel-
litus was significantly higher in the BSG 60.9% (n = 14) versus 39.1% 
(n = 69), p = .043 in the TO. The percentage smokers among TO was 
significantly higher (51.9% (n	=	69)	vs	21.7%	(n = 5), p < .001).
The baseline characteristics of the propensity scored matched 
cohort are also shown in Table 1. The BS-related outcomes are pre-
sented in Table 2. In the BSG, 48% patients underwent a sleeve gas-
trectomy (n = 11), 39% patients a RYGB (n = 9) and 13% patients GB 
(n = 3). The BSG had a median BMI of 42.3 kg/m2	(41.3–47.8)	before	
BS. BMI 1 year after BS was 33.9 (31.2–36.5).
3.2  |  Postoperative complications
The incidence of postoperative complications is shown in Table 3. 
Urinary tract infections (UTI) were more common in the BS (60.9% 
(n = 14) vs 31.6% (n	=	42),	OR	3.37;	95%	CI	1.35–8.40;	p	=	 .007).	
There were no significant differences between TO patients versus 
patients after BS in biopsy proven rejections, wound problems, or 
other complications. There were no significant differences between 
the matched cohort and the BSG.
Figure 2 shows the percentage of patients with a severe com-
plication divided by Clavien-Dindo grade. There was no significant 
difference in the incidence of severe complication between both 
groups. Table 4 shows an overview of the complications that were 
included.
3.3  |  Obesity-related morbidity in BS patients
Prior to bariatric surgery, 16 patients (69.6%) had a history of dia-
betes.	 Two	 of	 these	 patient	 (8.7%)	 were	 cured	 after	 undergoing	
bariatric surgery and did not need antidiabetic medication at time of 
transplantation.	At	1	year	after	transplantation,	two	patients	(8.7%)	
developed PTDM and started antidiabetic medication. This was 
similar to the rate of PTDM in the TO, in which 14 patients (10.5%) 
developed	PTDM	(OR:	0.82:95%	CI	[0.17–3.89],	p	=	.578).
One patient (4.3%) discontinued the use of antidiabetic medi-
cation and 1 patient (4.3%) did not need insulin anymore and met-
formin was sufficient. Of the 10 patients who had a follow-up of 
5 years, 6 patients (60%) had diabetes.
One	year	after	transplantation,	four	patients	(17.4%)	were	taken	
off	 antihypertensive	 medication.	 Four	 patients	 (17.4%)	 switched	
from combination therapy to monotherapy. Increased use of an-
tihypertensive medication was not observed. In two patient who 
underwent RYGB, oxalate nephropathy was observed in the kidney 
transplant during biopsy. In one of these patients, ESRD was ini-
tially	caused	by	hyperoxaluria.	No	transplants	were	 lost	to	oxalate	
nephropathy. Table 5 shows the postoperative complications after 





Weight gain 1 year post-transplantation was comparable among 
both	groups,	2	kg	(−5.5	to	8.5)	in	the	TO	and	0.8	kg	(−10.1	to	5.5)	in	
the BSG (p = .329).
BS before kidney 
transplantation (n = 23)
BMI at BS, median (IQR) 42.3	(41.3–47.8)
BMI at KTx, median (IQR) 33.6	(31.4–34.7)
Time between BS and KTx in months, median (IQR) 32.7	(17.2–65.2)
Time of dialysis between BS and KTx in months, median (IQR) 22	(13–37)
Type of BS
SG, n (%) 11	(47.8)
RYGB, n (%) 9 (39.1)
GB, n (%) 3 (13.0)
Estimated weight loss in kg 1 year after BS, median (IQR) 30.0	(23.0–37.0)




GB, gastric banding; IQR, interquartile range; Kg, kilograms; KTx, kidney transplantation; RYGB, 
Roux-en Y gastric bypass; SG, sleeve gastrectomy.
TA B L E  2 BS-related	outcome
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3.4  |  Patient survival
The minimal follow-up time was 1.2 years, and the maximum follow-
up was 21.5 years. The median time between KTx and BS in patients 
who	 underwent	 BS	 after	 transplant	 was	 6.87	 years	 (5.37–9.35).	
Follow-up of these patients was censored after the date of BS. In 
total, there were 25 (18.8%) deaths in the TO recipients and 2 in the 
BSG	(8.7%).	The	median	follow-up	was	5.1	years	 (2.7–8.1).	Eighty-
seven patients (56%) had a follow-up time longer than 5 years, 10 in 
the BSG (43%) and 58% in the TO (n	=	77).	The	90-day	mortality	rate	
was 0.8% (n	=	1)	in	the	TO	and	zero	in	the	BSG	(p = .853). The cause 
of	death	in	that	patient	was	a	cardiac	arrest.	After	5	years,	the	sur-
vival rate of the TO group was 90% compared with 85% of the BSG. 
There was no significant difference in patient survival between TO 
and BSG (log rank test: p = .845) (Figure 3). Survival rates were statis-
tically	tested	in	the	matched	cohort.	At	5	years	post-transplantation,	
patient survival rates were 81% in the matched TO cohort and 80% 
in BSG (log rank test: p	=	.724).	Multivariable	analysis	was	done	using	
preselected variables to identify risk factors for overall death and 
the effect of each risk factor is shown in Table 6. Bariatric status, dia-
betes mellitus, and dialysis status were included in Cox proportional 
hazards	multivariable	analysis.	Independent	risk	factors	for	all-cause	
mortality were dialysis treatment pre-transplantation (HR 2.55; 95% 
CI 1.03–6.34, p = .043) and having a medical history of diabetes mel-
litus (HR 2.41; 95% CI 1.11–5.22, p	=	.027).
3.5  |  Graft survival
In	total,	50	(37.6%)	grafts	were	lost	due	to	either	graft	failure	or	pa-
tient	death	in	the	TO	and	6	(26.1%)	in	the	BSG.	The	incidence	of	EGL	
was 6.1% (n = 8) in the TO compared with 4.3% (n = 1) in the BSG 
(p	=	 .790).	Figure	4	shows	the	death-censored	graft	survival	curve	
F I G U R E  2 Incidence	of	severe	postoperative	complications	according	to	the	Clavien-Dindo	classification.	BSG,	bariatric	surgery	group;	
TO, transplant only





Ureteral problems treated with dotter (n = 6)
Arrhythmia	treated	with	cardioversion	(n = 3)
DGF requiring hemodialysis (n = 30)
Grade IIIb Ureteral re-implantation (n = 6)
Respiratory insufficiency requiring artificial 
respiration (n = 1)
Grade IV Myocardial infarct requiring PCI (n = 2)
EGL	due	to	rejection	(n = 3)
EGL	due	to	thrombus	(n = 2)
Grade V Death (n = 1)
Abbreviation:	DGF,	delayed	graft	function;	EGL,	early	graft	loss;	PCI,	
percutaneous	coronary	intervention;	PCN,	percutaneous	nephrostomy.
TA B L E  5 Postoperative	complications	after	kidney	
transplantation in bariatric surgery patient divided by type of 
bariatric procedure
SG (n = 11) RYGB (n = 9)
GB 
(n = 3)
Myocardial infarct, n (%) 0 (0) 1 (11) 0 (0)
Renal artery thrombosis, 
n (%)
0 (0) 1 (11) 0 (0)
Biopsy proven rejection, 
n (%)
2 (18) 3 (33) 1 (33)
Wound infection, n (%) 2 (18) 1 (11) 0 (0)
DVT, n (%) 1 (0) 0 (0) 0 (0)
Abbreviations:	DVT,	deep	vein	thrombosis;	GB,	gastric	banding;	SG,	
sleeve gastrectomy; RYGB, Roux-en Y gastric bypass.
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of	the	two	groups.	No	statistically	significant	difference	was	found	
between the two groups (log rank test: p = .659). Death-censored 
graft	survival	after	5	years	was	78%	in	TO	and	65%	in	BSG.	Death-
censored graft survival was statistically tested in the matched co-
hort.	At	5	years	post-transplantation,	death-censored	graft	survival	
was 66% in the matched transplant only cohort and 64% in BSG (log 
rank test: p = .964).
Figure 5 shows the survival curve of the uncensored graft survival. 
Uncensored graft survival after 5 years was 84% in TO and 80% in 
BSG. The log rank test showed that there is no significant difference in 
overall graft survival between the BSG and TO (p	=	.704).	Uncensored	
graft	survival	was	statistically	tested	in	the	matched	cohort.	At	5	years	
post-transplantation,	 uncensored	 graft	 survival	 was	 70%	 in	 the	
matched TO cohort and 80% in BSG (log rank test: p = .869).
Multivariable analysis was done to identify risk factors for 
death-censored graft loss. The effect of each risk variable is shown 
in	Table	7.	Age	per	year,	BMI	per	point,	diabetes,	type	of	donor,	and	
bariatric status were included in the multivariable analysis. Having 
received a kidney from a deceased donor was an independent risk 
factor	 for	 death-censored	 graft	 loss	 (HR	 1.98;	 95%	 CI	 1.04–3.79,	
p = .038).
4  |  DISCUSSION
Patients who became eligible for KTx after BS after initial rejection 
due to obesity have similar outcome as matched transplant recipi-
ents with obesity class II and III. Furthermore, 5-year graft and pa-
tient survival after kidney transplantation did not differ between 
both groups.
In this cohort, the BSG had a median BMI of 42.3 kg/m2 before BS 
and the majority of patients were considered ineligible for transplan-
tation	based	on	the	fat	distribution.	After	BS,	the	median	BMI	was	
33.6 kg/m2 and all patients were found eligible for transplantation. If 
patients had not undergone BS, the majority of these patients would 
have remained on dialysis or would have never been transplanted. 
This finding is in line with other studies that report the use of BS 
in helping patients become eligible for KTx.21–24 In a retrospective 
study by Modanlou et al,24 29 waitlisted patients were referred to 
undergo BS and 20 of them proceeded with transplantation. Jamal 
F I G U R E  3 The	patient	survival	curve	post-transplant	of	recipients	with	obesity	class	II	and	III	compared	with	patients	who	underwent	
bariatric surgery. BSG, bariatric surgery group; TO, transplant only
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et al described 21 cases of BS in patients on dialysis of whom 18 
had lost sufficient weight and herewith becoming eligible for trans-
plantation. The survival advantage of KTx compared with dialysis 
stresses the importance of becoming eligible for transplantation.21 
Gill et al concluded that the survival advantage of KTx compared with 
dialysis is great across most BMI groups. The only exception were 
African	American	women	with	class	III	obesity.26 It is therefore ben-
eficial for the majority of patients with obesity to be transplanted. 
F I G U R E  4 The	death-censored	graft	survival	curve	post-transplant	of	recipients	with	obesity	class	II	and	III	compared	with	patients	who	
underwent BS prior to transplantation. BSG, bariatric surgery group; TO, transplant only
F I G U R E  5 The	uncensored	graft	survival	curve	post-transplant	of	recipients	with	obesity	class	II	and	III	compared	with	patients	who	
underwent BS prior to transplantation. BSG, bariatric surgery group; TO, transplant only
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As	this	study	shows,	having	undergone	BS	was	not	a	risk	factor	for	
patient death. Therefore, we can conclude that BS does not render 
additional risk of morbidity and mortality after KTx compared with 
the control group.
Patients who became transplantable after BS had similar out-
come	as	matched	patients	with	obesity	class	II	and	III.	No	decrease	
in complication rates was found in the BSG compared with the TO. 
This can possibly be explained by the fact that the majority of re-
cipients	were	still	obese	(BMI	IQR	31.4–34.7	kg/m2) at the time of 
transplantation, even though BS was performed. The main objective 
of BS in these particular patients is not achieving a healthy weight, 
but becoming eligible for transplantation by decreasing the amount 
of intra-abdominal fat. However, considering that the median BMI 
before BS was 42.3 kg/m2, patients did lose a considered amount of 
excess weight and it can therefore be concluded that BS is feasible 
in KTx candidates suffering from obesity.
More interestingly, multivariate analysis showed that every in-
crement in BMI adds nearly 8% risk of graft loss (HR 1.08, 95% CI: 
0.98–1.18, p	=	.093).	As	this	HR	is	not	statistically	significant,	it	does	
show a trend toward significance. This suggests that even in the 
transplant	recipients	with	obesity	class	II	or	higher	(BMI	≥	35)	every	
increment in BMI negatively effects graft survival. Therefore, weight 
loss should be recommended in every patient with obesity.
Also	noteworthy	is	the	high	percentage	of	PNF	of	2.3%	in	the	TO	
and 4.3% in the BSG.
In total, nine grafts were lost in the first 3 months after trans-
plantation.	The	occurrence	of	PNF	is	often	attributed	to	graft	char-
acteristics rather than recipient characteristic as it is more prevalent 
in	inferior	graft	from	older	donor	or	deceased	donors.	Although	the	
percentage of older donors or Extended Criteria donors (ECD) was 
comparable among groups, the TO more often receive grafts from a 
living	donor	(67.7%	vs	56.5%).
Another	notable	matter	is	the	high	number	of	thrombosis	in	both	
the TO (3.8%) and BSG (4.3%). This could probably be explained by 
the fact that obesity a risk factor is for developing thrombosis and 
obese patients are two to three times more likely to develop renal 
vein or artery thrombosis.27,28	As	 this	 study	only	 included	patient	
with	a	BMI	≥	35,	higher	numbers	of	thrombosis	are	to	be	expected.	
Furthermore, in this cohort two graft were lost due to thrombosis, 
showing the importance of preventing the development of renal 
thrombosis. In a study done by Van den Berg et al, the effect of 
perioperative antithrombotic therapy on the development of renal 
artery thrombosis was investigated.28 They concluded that with a 
stricter antithrombotic therapy, postoperative thromboembolic 
complications decrease. However, this was associated with higher 
risk of postoperative bleeding.
This study shows that having undergone bariatric surgery does 
not increase complications after KTx or negatively effects patient 
survival and graft survival. Therefore, we can conclude that BS is 
a safe method to establish long-term weight loss. The policy used 
by	most	transplant	centers	 in	The	Netherlands	of	withholding	KTx	
until a BMI below 35 kg/m2 is achieved can result in an extended 
period of dialysis or in patients not being transplanted at all, as they 
might never establish the required weight loss. This could eventually 
lead to higher morbidity and mortality rates than when choosing to 
perform a transplant in a patient with obesity class II and III obesity. 
However, benefits of bariatric surgery must weight against the risk 
of morbidity from extended dialysis prior to kidney transplantation. 
In our data, BSG received longer dialysis treatment than the TO and 
although not statistically significant, complications associated with 
dialysis such as cardiovascular event and wound complications are 
slightly higher in the BSG. In those patients who do not have a living 
donor available, BS can be used to bridge the time on the waiting 
list for a deceased kidney offer. This time can be used to get these 
patients in optimal condition for KTx.
Wound complications are among the major challenges when per-
forming kidney transplantation in obese patients.17 In our cohort, the 
incidence of wound problems was 11.3% among TO recipients and 
13% in the BSG. This percentage is higher compared with the inci-
dence	of	7%	that	is	reported	in	the	general	KTx	population.25 This is 
probably due to the obesity in both TO and BSG which is known to 
increase wound problems in kidney transplant recipients.16,17	As	pre-
viously mentioned, excessive abdominal fat impairs the view of the 
surgical field which can hinder the implantation of the kidney. Robot-
assisted	kidney	transplantation	(RAKT)	can	be	a	feasible	alternative	in	
obese kidney transplant recipients, because it provides an enhanced 
view of the surgical field and can be performed through a smaller in-
cision.29,30	Tzvetanov	et	al	reviewed	six	studies	about	RAKT	and	con-
cluded that there is a decrease of wound problems in obese recipients 
after	RAKT	compared	with	open	surgery.30 Spaggiari et al performed 
28	RAKTs	in	patients	with	a	BMI	above	30	kg/m2 between 2009 and 
2013	and	observed	no	wound	infection	in	patients	undergoing	RAKT	
compared with 28.6% in the open surgery group.31
In two patients, oxalate nephropathy was observed after RYGB. 
Oxalate nephropathy is a complication often seen in patients with 
inflammatory bowel diseases (IBD), ileal resection, and Roux-en-Y 
gastric bypass (RYGB).32 Due enteric hyperoxaluria, oxalate accumu-
lates in the kidney and can cause nephrolithiasis and nephrocalci-
nosis.	Literature	has	shown	that	even	though	weight	loss	after	SG	is	
comparable to RYGB, complication rates are much lower.33 In obese 
transplant candidates, we have a preference for SG, due to lower 
complication rates and a lower to no risk of oxalate nephropathy.
TA B L E  7 Multivariable	analysis	of	death-censored	graft	survival	
using	Cox	proportional	hazards	model
Multivariable analysis
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This study has several limitations. BS was not considered in 
kidney transplant candidates up until recently, and therefore, only 
a small number of patients who had undergone both procedures 
were included. The present study is a retrospective, single-center 
analysis. There is a potential for selection bias as the decision for 
eligibility for KTx is depending on the opinion of a surgeon rather 
than	an	objective	measure.	We	hypothesized	that	obese	male	can-
didates would more often require bariatric surgery, as they are 
more likely to have visceral fat distribution. However, this did not 
turn out to be the case. In our opinion, it is difficult to establish an 
objective measure for eligibility through imaging in this group of 
patients and eligibility based on the physical examinations remains 
the standard.
It has been shown that recipient obesity influences the out-
come of kidney transplantation in the long-term rather than the 
short-term. This study, to our knowledge, presents the longest fol-
low-up in patients undergoing both kidney transplantation and BS. 
However, longer follow-up is needed to form a conclusive answer to 
whether or not successful BS positively influences graft and patient 
survival in patient with obesity class II and III. The effectiveness of 
improving eligibility in potential transplant recipients through BS 
needs to be further determined in order to actively refer patients 
to BS.
In conclusion, patients who became eligible for KTx after BS after 
initial rejection due to obesity have similar results of KTx as matched 
kidney transplant patient with obesity class II and III who were el-
igible while being obese. Kidney transplantation after BS does not 
negatively affect the outcome of KTx compared with transplanting 
patients with obesity class II or higher.
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